Publications by authors named "Helmut Maecke"

Claim this Profile
P
Pyridyl-Ala in the third position of radiolabeled somatostatin antagonists: the effect of regioisomeric substitution.
Rosalba Mansi, Natalie Bertarelli, Luigi Del Pozzo, Sandra Zanger, Tais Basaco Bernabeu, Helmut Maecke

EJNMMI Radiopharm Chem· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Long-Term Tumor Control Following Targeted Alpha Therapy (TAT) of Low-Grade Gliomas (LGGs): A New Treatment Paradigm?
Leszek Krolicki, Jolanta Kunikowska, Dominik Cordier, Nedelina Slavova, Henryk Koziara, Helmut R Maecke

Int J Mol Sci· October 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
[
[In]In-CP04 as a novel cholecystokinin-2 receptor ligand with theranostic potential in patients with progressive or metastatic medullary thyroid cancer: final results of a GRAN-T-MTC Phase I clinical trial.
Luka Lezaic, Paola Anna Erba, Clemens Decristoforo, Katja Zaletel, Renata Mikolajczak, Helmut Maecke

Eur J Nucl Med Mol Imaging· February 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Detection of Insulinomas Using Dual-Time-Point 68Ga-DOTA-Exendin 4 PET/CT.
Kerstin Michalski, Katharina Laubner, Christian Stoykow, Mohamed Aymen Omrane, Helmut R Maecke

Clin Nucl Med· July 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Accuracy of [Ga]Ga-RM2-PET/CT for diagnosis of primary prostate cancer compared to histopathology.
Thomas F Fassbender, Florian Schiller, Michael Mix, Helmut R Maecke, Selina Kiefer

Nucl Med Biol· March 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A novel CCK2/gastrin receptor-localizing radiolabeled peptide probe for personalized diagnosis and therapy of patients with progressive or metastatic medullary thyroid carcinoma: a multicenter phase I GRAN-T-MTC study.
Paola A Erba, Helmut Maecke, Renata Mikolajczak, Clemens Decristoforo, Katja Zaletel

Pol Arch Intern Med· December 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The tetraamine chelator outperforms HYNIC in a new technetium-99m-labelled somatostatin receptor 2 antagonist.
Keelara Abiraj, Samer Ursillo, Maria Luisa Tamma, Svetlana N Rylova, Beatrice Waser, Helmut R Maecke

EJNMMI Res· August 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Radiochemistry and Preclinical PET Imaging of Ga-Desferrioxamine Radiotracers Targeting Prostate-Specific Membrane Antigen.
Eleni Gourni, Luigi Del Pozzo, Mark Bartholomä, Yvonne Kiefer, Philipp T Meyer, Helmut R Maecke

Mol Imaging· July 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The somatostatin receptor 2 antagonist 64Cu-NODAGA-JR11 outperforms 64Cu-DOTA-TATE in a mouse xenograft model.
Svetlana N Rylova, Christian Stoykow, Luigi Del Pozzo, Keelara Abiraj, Maria Luisa Tamma, Helmut R Maecke

PLoS One· July 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety, Biodistribution, and Radiation Dosimetry of Ga-OPS202 in Patients with Gastroenteropancreatic Neuroendocrine Tumors: A Prospective Phase I Imaging Study.
Guillaume P Nicolas, Seval Beykan, Hakim Bouterfa, Jens Kaufmann, Andreas Bauman, Helmut R Maecke

J Nucl Med· June 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Gastrin-releasing Peptide Receptor Imaging in Breast Cancer Using the Receptor Antagonist (68)Ga-RM2 And PET.
Christian Stoykow, Thalia Erbes, Helmut R Maecke, Stefan Bulla, Mark Bartholomä

Theranostics· October 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Reply: Diabetes Mellitus and Its Effects on All-Cause Mortality After Radiopeptide Therapy for Neuroendocrine Tumors: Methodologic Issues.
Maria Umlauft, Piotr Radojewski, Petar-Marko Spanjol, Rebecca Dumont, Nicolas Marincek, Helmut R Maecke

J Nucl Med· September 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Approaches to Multireceptor Targeting: Hybrid Radioligands, Radioligand Cocktails, and Sequential Radioligand Applications.
Jean Claude Reubi, Helmut R Maecke

J Nucl Med· September 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Radioiodinated Exendin-4 Is Superior to the Radiometal-Labelled Glucagon-Like Peptide-1 Receptor Probes Overcoming Their High Kidney Uptake.
Tilman Läppchen, Roswitha Tönnesmann, Jos Eersels, Philipp T Meyer, Helmut R Maecke

PLoS One· August 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Neodymium-140 DOTA-LM3: Evaluation of an Generator for PET with a Non-Internalizing Vector.
Gregory W Severin, Lotte K Kristensen, Carsten H Nielsen, Jesper Fonslet, Andreas I Jensen, Helmut Maecke

Front Med (Lausanne)· July 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Radiopharmaceuticals for somatostatin receptor imaging.
Renata Mikołajczak, Helmut R Maecke

Nucl Med Rev Cent East Eur· March 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The prognostic and predictive value of sstr-immunohistochemistry and sstr-targeted imaging in neuroendocrine tumors.
Philippe Brunner, Ann-Catherine Jörg, Katharina Glatz, Lukas Bubendorf, Piotr Radojewski, Helmut R Maecke

Eur J Nucl Med Mol Imaging· March 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Approaches to improve metabolic stability of a statine-based GRP receptor antagonist.
Ilinca Popp, Luigi Del Pozzo, Beatrice Waser, Jean Claude Reubi, Philipp T Meyer, Helmut R Maecke

Nucl Med Biol· February 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Diabetes Mellitus and Its Effects on All-Cause Mortality After Radiopeptide Therapy for Neuroendocrine Tumors.
Maria Umlauft, Piotr Radojewski, Petar-Marko Spanjol, Rebecca Dumont, Nicolas Marincek, Helmut R Maecke

J Nucl Med· January 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Reply: Somatostatin Receptor-Targeted Radiopeptide Therapy in Patients with Progressive Unresectable Meningioma.
Piotr Radojewski, Rebecca A Dumont, Nicolas Marincek, Philippe Brunner, Jan Müller-Brand, Helmut R Maecke

J Nucl Med· October 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Delphic consensus assessment: imaging and biomarkers in gastroenteropancreatic neuroendocrine tumor disease management.
Kjell Oberg, Eric Krenning, Anders Sundin, Lisa Bodei, Mark Kidd, Helmut Maecke

Endocr Connect· September 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Approaches to Improve the Pharmacokinetics of Radiolabeled Glucagon-Like Peptide-1 Receptor Ligands Using Antagonistic Tracers.
Svetlana N Rylova, Beatrice Waser, Luigi Del Pozzo, Roswitha Tönnesmann, Rosalba Mansi, Helmut R Maecke

J Nucl Med· August 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Preclinical pharmacokinetics, biodistribution, radiation dosimetry and toxicity studies required for regulatory approval of a phase I clinical trial with (111)In-CP04 in medullary thyroid carcinoma patients.
Theodosia Maina, Mark W Konijnenberg, Petra KolencPeitl, Piotr Garnuszek, Berthold A Nock, Helmut Maecke

Eur J Pharm Sci· August 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
From preclinical development to clinical application: Kit formulation for radiolabelling the minigastrin analogue CP04 with In-111 for a first-in-human clinical trial.
Dariusz Pawlak, Christine Rangger, Petra Kolenc Peitl, Piotr Garnuszek, Michał Maurin, Helmut Maecke

Eur J Pharm Sci· March 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
AMD3100: A Versatile Platform for CXCR4 Targeting (68)Ga-Based Radiopharmaceuticals.
Sophie Poty, Eleni Gourni, Pauline Désogère, Frédéric Boschetti, Christine Goze, Helmut R Maecke

Bioconjug Chem· March 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis